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In this symposium, we discussed the usefulness and feasibility of current chemotherapy protocols for
urological cancers including renal cell carcinoma, urothelial cancer, prostate cancer and testicular cancer.
(1) Renal cell carcinoma : Although molecular targeted therapy is now becoming a standard therapy for
metastatic renal cell carcinoma, the current situation is somehow confusing due to unknown adverse effects
and lack of guidelines for indication of each compound. (2) Urothelial cancer : gemcitabine and cisplatin
(GC) therapy is taking over methotrexate, vinblastine, doxorubicin and cisplatin (MVAC) therapy because of
less toxicity. We focused on a novel biomarker, hENT1, to predict the anti tumor effect of GC therapy. (3)
Prostate cancer : The survival beneﬁt of docetaxel for castration resistant prostate cancer was proven by large
clinical trials. We dealt with uracil and tegafur (UFT) therapy which has been widely used in Japan. (4)
Testicular cancer : It is needles to say that BEP therapy was established as a standard induction therapy for
metastatic testicular cancer. However, regarding salvage chemotherapy, it is still controversial whether
vinblastine, ifosphamide and platinum (VIP), paclitaxel, ifosphamide and platinum (TIP) and high dose
chemotherapy should be selected.
(Hinyokika Kiyo 57 : 151-152, 2011)
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